Jon Zabaleta1, Tomohiko Iida2, Pierre E Falcoz3, Samer Salah4, José R Jarabo5, Arlene M Correa6, Maria G Zampino7, Takashi Matsui8, Sukki Cho9, Francesco Ardissone10, Kazuhiro Watanabe11, Michel Gonzalez12, Pascal Gervaz13, Jose I Emparanza14, Víctor Abraira15. 1. Thoracic Surgery Service, Hospital Universitario Donostia, Paseo Dr Beguiristain s/n, Donostia, 20014, Gipuzkoa, Spain. Electronic address: jon.zabaletajimenez@osakidetza.eus. 2. Department of Thoracic Surgery, Kimitsu Central Hospital, Chiba, Japan. 3. Department of Thoracic Surgery, Strasbourg University Hospital, Strasbourg, France. 4. Medical Oncology Department, King Hussein Cancer Center, Amman, Jordan. 5. Department of Thoracic Surgery, Hospital Clínico San Carlos, Madrid, Spain. 6. Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, USA. 7. Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy. 8. Department of Colorectal Surgery, Tochigi Cancer Center, Tochigi, Japan. 9. Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seoul, South Korea. Electronic address: skcho@snubh.org. 10. Department of Oncology, Unit of Thoraic Surgery, University of Torino, Italy. 11. Department of Surgical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. 12. Service de Chirurgie Thoracique, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. 13. Department of Surgery, University Hospital Geneva, Geneva, Switzerland. 14. Clinical Epidemiology Unit, Hospital Universitario Donostia, UPV/EHU, CIBER-ESP, CASPe, Biodonostia, Donostia, Spain. 15. Unidad de Bioestadística Clínica, Hospital Universitario Ramón y Cajal, IRYCIS, CIBER-ESP, Madrid, Spain.
Abstract
OBJECTIVES: To assess the impact of a history of liver metastases on survival in patients undergoing surgery for lung metastases from colorectal carcinoma. METHODS: We reviewed recent studies identified by searching MEDLINE and EMBASE using the Ovid interface, with the following search terms: lung metastasectomy, pulmonary metastasectomy, lung metastases and lung metastasis, supplemented by manual searching. Inclusion criteria were that the research concerned patients with lung metastases from colorectal cancer undergoing surgery with curative intent, and had been published between 2007 and 2014. Exclusion criteria were that the paper was a review, concerned surgical techniques themselves (without follow-up), and included patients treated non-surgically. Using Stata 14, we performed aggregate data and individual data meta-analysis using random-effect and Cox multilevel models respectively. RESULTS: We collected data on 3501 patients from 17 studies. The overall median survival was 43 months. In aggregate data meta-analysis, the hazard ratio for patients with previous liver metastases was 1.19 (95% CI 0.90-1.47), with low heterogeneity (I2 4.3%). In individual data meta-analysis, the hazard ratio for these patients was 1.37 (95% CI 1.14-1.64; p < 0.001). Multivariate analysis identified the following factors significantly affecting survival: tumour-infiltrated pulmonary lymph nodes (p < 0.001), type of resection (p = 0.005), margins (p < 0.001), carcinoembryonic antigen levels (p < 0.001), and number and size of lung metastases (both p < 0.001). CONCLUSIONS: A history of liver metastases is a negative prognostic factor for survival in patients with lung metastases from colorectal cancer. We registered the meta-analysis protocol in PROSPERO (CRD42015017838).
OBJECTIVES: To assess the impact of a history of liver metastases on survival in patients undergoing surgery for lung metastases from colorectal carcinoma. METHODS: We reviewed recent studies identified by searching MEDLINE and EMBASE using the Ovid interface, with the following search terms: lung metastasectomy, pulmonary metastasectomy, lung metastases and lung metastasis, supplemented by manual searching. Inclusion criteria were that the research concerned patients with lung metastases from colorectal cancer undergoing surgery with curative intent, and had been published between 2007 and 2014. Exclusion criteria were that the paper was a review, concerned surgical techniques themselves (without follow-up), and included patients treated non-surgically. Using Stata 14, we performed aggregate data and individual data meta-analysis using random-effect and Cox multilevel models respectively. RESULTS: We collected data on 3501 patients from 17 studies. The overall median survival was 43 months. In aggregate data meta-analysis, the hazard ratio for patients with previous liver metastases was 1.19 (95% CI 0.90-1.47), with low heterogeneity (I2 4.3%). In individual data meta-analysis, the hazard ratio for these patients was 1.37 (95% CI 1.14-1.64; p < 0.001). Multivariate analysis identified the following factors significantly affecting survival: tumour-infiltrated pulmonary lymph nodes (p < 0.001), type of resection (p = 0.005), margins (p < 0.001), carcinoembryonic antigen levels (p < 0.001), and number and size of lung metastases (both p < 0.001). CONCLUSIONS: A history of liver metastases is a negative prognostic factor for survival in patients with lung metastases from colorectal cancer. We registered the meta-analysis protocol in PROSPERO (CRD42015017838).
Authors: Federico Davini; Sara Ricciardi; Carmelina C Zirafa; Gaetano Romano; Greta Alì; Gabriella Fontanini; Franca M A Melfi Journal: Int J Colorectal Dis Date: 2019-11-04 Impact factor: 2.571
Authors: Elena Prisciandaro; Laurens J Ceulemans; Dirk E Van Raemdonck; Herbert Decaluwé; Paul De Leyn; Luca Bertolaccini Journal: J Thorac Dis Date: 2022-07 Impact factor: 3.005
Authors: Raghav Chandra; John D Karalis; Charles Liu; Gilbert Z Murimwa; Josiah Voth Park; Christopher A Heid; Scott I Reznik; Emina Huang; John D Minna; Rolf A Brekken Journal: Cancers (Basel) Date: 2021-12-09 Impact factor: 6.639